GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Senzime AB (OSTO:SEZI) » Definitions » Debt-to-Asset

Senzime AB (OSTO:SEZI) Debt-to-Asset : 0.03 (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Senzime AB Debt-to-Asset?

Senzime AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr2.65 Mil. Senzime AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr8.58 Mil. Senzime AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was kr409.85 Mil. Senzime AB's debt to asset for the quarter that ended in Mar. 2024 was 0.03.


Senzime AB Debt-to-Asset Historical Data

The historical data trend for Senzime AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senzime AB Debt-to-Asset Chart

Senzime AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.01 0.01 0.04 0.03

Senzime AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.04 0.03 0.03 0.03

Competitive Comparison of Senzime AB's Debt-to-Asset

For the Medical Devices subindustry, Senzime AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senzime AB's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Senzime AB's Debt-to-Asset falls into.



Senzime AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Senzime AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Senzime AB's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(2.648 + 8.575) / 409.849
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Senzime AB  (OSTO:SEZI) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Senzime AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Senzime AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Senzime AB (OSTO:SEZI) Business Description

Traded in Other Exchanges
Address
Ulls vag 41, Uppsala, SWE, 756 51
Senzime AB, a medical technology company, develops, manufactures, and markets patient monitoring systems for monitoring patients. Its solutions are designed to ensure maximum patient benefit, reduce complications associated with surgery and anesthesia, and decrease healthcare costs. Its product includes TetraGraph and TetraSens, ExSpiron, TetraSens Pediatric, and TetraConnect. Its geographical segments include Sweden, the United States, Europe/Oceania, and Asia.

Senzime AB (OSTO:SEZI) Headlines

No Headlines